Lung Cancer Treatment Drugs Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis
MARKET INTRODUCTION
Lung cancer treatment can be treated with two types of drugs, such as innovative and generic drugs. The drugs are used to provide chemotherapy or immunotherapy, which is decided based on the type of cells that cause lung cancer. Various companies are involved in the development of lung cancer and are receiving approval for their products. For instance, in May 2020, the US FDA has approved Tabrecta (capmatinib) to treat non-small cell lung cancer (NSCLC) in adults. The drug can treat NSCLC with specific mutations, and it is expected to enhance the growth of the market in the following years.
MARKET DYNAMICS
The lung cancer treatment drugs market growth is anticipated to grow due to increasing lung cancer incidences due to higher consumption of tobacco, rising pollution, and increasing approvals for drugs treating lung cancer. The continue research and development in the pharmaceutical and biotechnology sectors are expected to serve significant growth opportunities for market growth.
MARKET SCOPE
The "Lung Cancer Treatment Drugs Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of lung cancer treatment drugs market with detailed market segmentation by type, drug class and distribution channel. The lung cancer treatment drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in lung cancer treatment drugs market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The lung cancer treatment drugs market is segmented on the basis of, type, drug class and distribution channel. Based on type, the market is divided into non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC). Based on drug class, the market is divided into antimetabolites, alkylating agents, mitotic inhibitors, EGFR inhibitors, multikinase inhibitors, and others. And based on distribution channel, the market is classified as hospital and retail pharmacies, online distribution, and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the lung cancer treatment drugs market based on various segments. It also provides market size and forecast estimates from year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The lung cancer treatment drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting lung cancer treatment drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the lung cancer treatment drugs market in these regions.
By Type [Non-small Cell Lung Cancer
By Drug Class
By Distribution Channel
MARKET PLAYERS
The report covers key developments in the lung cancer treatment drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from lung cancer treatment drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for lung cancer treatment drugs in the global market. Below mentioned is the list of few companies engaged in the lung cancer treatment drugs market.
The report also includes the profiles of key players in lung cancer treatment drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
Lung cancer treatment can be treated with two types of drugs, such as innovative and generic drugs. The drugs are used to provide chemotherapy or immunotherapy, which is decided based on the type of cells that cause lung cancer. Various companies are involved in the development of lung cancer and are receiving approval for their products. For instance, in May 2020, the US FDA has approved Tabrecta (capmatinib) to treat non-small cell lung cancer (NSCLC) in adults. The drug can treat NSCLC with specific mutations, and it is expected to enhance the growth of the market in the following years.
MARKET DYNAMICS
The lung cancer treatment drugs market growth is anticipated to grow due to increasing lung cancer incidences due to higher consumption of tobacco, rising pollution, and increasing approvals for drugs treating lung cancer. The continue research and development in the pharmaceutical and biotechnology sectors are expected to serve significant growth opportunities for market growth.
MARKET SCOPE
The "Lung Cancer Treatment Drugs Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of lung cancer treatment drugs market with detailed market segmentation by type, drug class and distribution channel. The lung cancer treatment drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in lung cancer treatment drugs market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The lung cancer treatment drugs market is segmented on the basis of, type, drug class and distribution channel. Based on type, the market is divided into non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC). Based on drug class, the market is divided into antimetabolites, alkylating agents, mitotic inhibitors, EGFR inhibitors, multikinase inhibitors, and others. And based on distribution channel, the market is classified as hospital and retail pharmacies, online distribution, and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the lung cancer treatment drugs market based on various segments. It also provides market size and forecast estimates from year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The lung cancer treatment drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting lung cancer treatment drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the lung cancer treatment drugs market in these regions.
Lung Cancer Treatment Drugs Market Report Analysis
Lung Cancer Treatment Drugs Market
-
CAGR (2023 - 2031)XX% -
Market Size 2023
US$ XX Million -
Market Size 2031
US$ XX Million
Report Coverage
- Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Key future trends
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- Industry landscape and competition analysis & recent developments
- Detailed company profiles
- Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
Key Players
- AstraZeneca
- Eli Lilly and Company
- GlaxoSmithKline plc
- Pfizer Inc
- F Hoffmann La Roche Ltd
- Sanofi
- Boehringer Ingelheim International GmbH
- Novartis AG
- Merck and Co Inc
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
By Type [Non-small Cell Lung Cancer
- NSCLC
- Small Cell Lung Cancer
By Drug Class
- Antimetabolites
- Alkylating Agents
- Mitotic Inhibitors
- EGFR Inhibitors
- Multikinase Inhibitors
- Others
By Distribution Channel
- Hospital and Retail Pharmacies
- Online Distribution
- Others
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
The report covers key developments in the lung cancer treatment drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from lung cancer treatment drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for lung cancer treatment drugs in the global market. Below mentioned is the list of few companies engaged in the lung cancer treatment drugs market.
The report also includes the profiles of key players in lung cancer treatment drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- AstraZeneca
- Eli Lilly and Company
- GlaxoSmithKline plc
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Sanofi
- Boehringer Ingelheim International GmbH
- Novartis AG
- Merck and Co., Inc.
- Daiichi Sankyo Company, Limited
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
Lung Cancer Treatment Drugs Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ XX Million |
| Market Size by 2031 | US$ XX Million |
| Global CAGR (2023 - 2031) | XX% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Type [Non-small Cell Lung Cancer
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
|
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
The List of Companies
1. AstraZeneca
2. Eli Lilly and Company
3. GlaxoSmithKline plc
4. Pfizer Inc.
5. F. Hoffmann-La Roche Ltd
6. Sanofi
7. Boehringer Ingelheim International GmbH
8. Novartis AG
9. Merck and Co., Inc.
10. Daiichi Sankyo Company, Limited
1. AstraZeneca
2. Eli Lilly and Company
3. GlaxoSmithKline plc
4. Pfizer Inc.
5. F. Hoffmann-La Roche Ltd
6. Sanofi
7. Boehringer Ingelheim International GmbH
8. Novartis AG
9. Merck and Co., Inc.
10. Daiichi Sankyo Company, Limited
Get Free Sample For